Importance: Up to 20% of @entity1 undergoing thyroidectomy develop @entity3747 after surgery. Although usually transient, severe symptomatic @entity3747 may occur. @entity15896 (recombinant @entity1 parathyroid hormone 1-34) therapy can rapidly raise @entity460 levels. Objective: To test the hypothesis that @entity15896 therapy in @entity1 with @entity261 would expedite relief of symptomatic @entity3747 and reduce the duration of hospitalization compared with standard treatment. Design, Setting, and @entity1 : Case series of all hospitalized @entity1 18 years or older treated with @entity15896 for symptomatic postthyroidectomy @entity3747 occurring immediately after thyroidectomy at Mayo Clinic, Rochester, Minnesota, between January 1, 2008, and June 30, 2014. A secondary analysis was performed with matched control and cohort groups having postthyroidectomy @entity3747 of similar degree who received standard treatment only. @entity1 included 8 hospitalized @entity1 who received @entity15896 therapy after 24 hours of standard treatment (cases) and eight control @entity1 selected from a cohort of 1193 thyroidectomies were matched for age, sex, body mass index, and nadir @entity460 levels. Intervention: @entity15896 therapy (20   g twice daily) subcutaneously for 1 week, with the option of continuing at 20   g/d for up to 3 weeks. Main Outcomes and Measures: Safety, symptom resolution, @entity460 supplementation, and duration of hospitalization. Results: Among the 16 case and control @entity1 the median nadir @entity460 level was 7.1 mg/dL in both groups. Most @entity1 underwent thyroidectomy for @entity259 . @entity15896 therapy was safe, with no adverse events noted, and completely eliminated symptomatic @entity3747 in all treated @entity1 within 24 hours of initiation. Hospital discharge occurred at a median of 1.0 day (interquartile range, 1.0-1.0 day) after @entity15896 therapy initiation among cases vs 2.5 days (interquartile range, 1.8-3.0 days) after the equivalent clinical point was reached in controls (P   =   .01). This value was 2.0 days in the source cohort (P   =   .02). On hospital discharge, @entity1 had similar @entity460 levels. Six months after surgery, all @entity1 treated with @entity15896 showed partial or complete parathyroid recovery. @entity460 supplementation and @entity460 levels were comparable between the groups. Conclusions and Relevance: In this pilot study, @entity15896 therapy in @entity1 with @entity261 was safe, rapidly eliminated @entity14645 symptoms, and likely reduced the duration of hospitalization. Given the limitations of this small study, a large-scale randomized trial is needed to verify these results and to assess the long-term effect of @entity15896 therapy on clinical outcomes.

@entity15896 Therapy and Reduced Postoperative Hospitalization for Postsurgical XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'Participants'] @entity3747 :: ('MESH:D006996', 'Disease') :: ['hypocalcemia'] @entity15896 :: ('MESH:D019379', 'Chemical') :: ['Teriparatide', 'Teriparatide acetate', 'teriparatide'] @entity261 :: ('MESH:D007011', 'Disease') :: ['postthyroidectomy hypoparathyroidism'] @entity14645 :: ('MESH:C562689', 'Disease') :: ['hypocalcemic'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']
@entity261 :: (MESH:D007011,Disease) :: ['Hypoparathyroidism']
